NEW YORK (GenomeWeb News) — PerkinElmer on Monday said it plans to buy back as much as 10 million shares of its common stock over the next four years.

PerkinElmer’s board authorized the buyback, which will be made over the open market or “through privately negotiated transactions,” the company said.

Two weeks ago, PerkinElmer reported that third-quarter revenues rose 7 percent as profirs slid 7 percent.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.